These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 34502562)

  • 1. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
    Zaky A; Glastras SJ; Wong MYW; Pollock CA; Saad S
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease.
    Zhong C; Dai Z; Chai L; Wu L; Li J; Guo W; Zhang J; Zhang Q; Xue C; Lin H; Luo Q; Cai K
    J Clin Lab Anal; 2021 Dec; 35(12):e24062. PubMed ID: 34689373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective.
    Das S; Gnanasambandan R
    Life Sci; 2023 Mar; 316():121414. PubMed ID: 36682521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease.
    Tao P; Ji J; Wang Q; Cui M; Cao M; Xu Y
    Front Immunol; 2022; 13():1080456. PubMed ID: 36601125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of Gut Microbial Metabolites in Diabetic Kidney Disease.
    Fang Q; Liu N; Zheng B; Guo F; Zeng X; Huang X; Ouyang D
    Front Endocrinol (Lausanne); 2021; 12():636175. PubMed ID: 34093430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis.
    Li L; Wei T; Liu S; Wang C; Zhao M; Feng Y; Ma L; Lu Y; Fu P; Liu J
    J Cell Mol Med; 2021 Jan; 25(2):960-974. PubMed ID: 33280239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury.
    Cai K; Ma Y; Cai F; Huang X; Xiao L; Zhong C; Ren P; Luo Q; Chen J; Han F
    Endocrine; 2022 May; 76(2):294-303. PubMed ID: 35246764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabesity and mood disorders: Multiple links through the microbiota-gut-brain axis.
    Farzi A; Hassan AM; Zenz G; Holzer P
    Mol Aspects Med; 2019 Apr; 66():80-93. PubMed ID: 30513310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Connection between gut microbiome and the development of obesity.
    Zhi C; Huang J; Wang J; Cao H; Bai Y; Guo J; Su Z
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):1987-1998. PubMed ID: 31367997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Intestinal Microbiota Composition in Early and Late Stages of Diabetic Kidney Disease.
    Zhang L; Lu QY; Wu H; Cheng YL; Kang J; Xu ZG
    Microbiol Spectr; 2023 Aug; 11(4):e0038223. PubMed ID: 37341590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota induces DNA methylation via SCFAs predisposing obesity-prone individuals to diabetes.
    Guo W; Zhang Z; Li L; Liang X; Wu Y; Wang X; Ma H; Cheng J; Zhang A; Tang P; Wang CZ; Wan JY; Yao H; Yuan CS
    Pharmacol Res; 2022 Aug; 182():106355. PubMed ID: 35842183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM).
    Tanase DM; Gosav EM; Neculae E; Costea CF; Ciocoiu M; Hurjui LL; Tarniceriu CC; Maranduca MA; Lacatusu CM; Floria M; Serban IL
    Nutrients; 2020 Dec; 12(12):. PubMed ID: 33276482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
    Halmos T; Suba I
    Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in
    Yan H; Zhang Y; Lin X; Huang J; Zhang F; Chen C; Ren H; Zheng S; Yang J; Hui S
    Int J Food Sci Nutr; 2024 May; 75(3):264-276. PubMed ID: 38238900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Human Gut Microbiota.
    Harmsen HJ; de Goffau MC
    Adv Exp Med Biol; 2016; 902():95-108. PubMed ID: 27161353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tangshen Formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism.
    Chen DQ; Zhang HJ; Zhang W; Feng K; Liu H; Zhao HL; Li P
    Exp Gerontol; 2024 Apr; 188():112393. PubMed ID: 38458480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota dysbiosis -associated obesity and its involvement in cardiovascular diseases and type 2 diabetes. A systematic review.
    Hamjane N; Mechita MB; Nourouti NG; Barakat A
    Microvasc Res; 2024 Jan; 151():104601. PubMed ID: 37690507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A.
    Li YJ; Chen X; Kwan TK; Loh YW; Singer J; Liu Y; Ma J; Tan J; Macia L; Mackay CR; Chadban SJ; Wu H
    J Am Soc Nephrol; 2020 Jun; 31(6):1267-1281. PubMed ID: 32358041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiota and Complications of Type-2 Diabetes.
    Iatcu CO; Steen A; Covasa M
    Nutrients; 2021 Dec; 14(1):. PubMed ID: 35011044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.